Amarillo Biosciences (OTCMKTS:AMAR) and Harrow Health (NASDAQ:HROW) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.
Risk and Volatility
Amarillo Biosciences has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. Comparatively, Harrow Health has a beta of 0.06, suggesting that its share price is 94% less volatile than the S&P 500.
33.1% of Harrow Health shares are owned by institutional investors. 12.4% of Harrow Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Amarillo Biosciences and Harrow Health’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Amarillo Biosciences||$80,000.00||201.10||-$1.34 million||N/A||N/A|
|Harrow Health||$41.37 million||3.24||$14.63 million||$0.61||8.72|
Harrow Health has higher revenue and earnings than Amarillo Biosciences.
This is a breakdown of recent ratings and price targets for Amarillo Biosciences and Harrow Health, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
This table compares Amarillo Biosciences and Harrow Health’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Harrow Health beats Amarillo Biosciences on 7 of the 9 factors compared between the two stocks.
Amarillo Biosciences Company Profile
Amarillo Biosciences, Inc. engages in the development of biologics for the treatment of human and animal diseases. The company owns or licenses five issued patents related to the low-dose oral delivery of interferon; and owns one issued patent on its dietary supplement, Maxisal. It focuses on research for the treatment of human disease indications primarily influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon alpha. Amarillo Biosciences, Inc. was founded in 1984 and is based in Amarillo, Texas.
Harrow Health Company Profile
Harrow Health, Inc. owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients. The company also develops and commercializes therapeutics for the ocular surface diseases. In addition, it provides patent-pending preservative-free topical eye drop drug candidates, including SURF-100, an immunosuppressive drug that inhibits t-cell proliferation and replication in the dry eye disease (DED); SURF-200 for the patients with episodic DED; and SURF-300, a combination of a low-dose of doxycycline and a proprietary powderized triglyceride Omega-3 for the refractory DED patients with chronic DED symptoms. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.
Receive News & Ratings for Amarillo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarillo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.